Bioequivalence Evaluation of Rilmenidine in Healthy Volunteers

Abstract

The bioavailability of two rilmenidine tablet formulations was compared in healthy male (17) and female (8) subjects, aged 18 to 36 years, during a laboratory-blind, randomized, two-treatment, two-period, cross-over study under fasting conditions. In each treatment phase subjects received a single dose of 1.544 mg rilmenidine dihydrogen phosphate (CAS 85409-38-7), equivalent to 1 mg rilmenidine (CAS 54187-04-1). Consecutive dosing was separated by a drug-free wash-out period of 7 d. Following each dosing, serial venous blood samples were collected over a period of 48 h for the determination of plasma rilmenidine concentrations by means of a validated LC-MS/MS method. The most frequently reported drug-related adverse events were dizziness and headache ranging from mild to moderate in intensity. The geometric mean C_max of rilmenidine for the reference and test products was 3.73 and 3.97 ng/ml, respectively. The corresponding geometric mean AUC(0–∞) was 34.0 and 35.1 ng • h/ml. T_max for both products under investigation appeared at 1.33 h. The test product was shown to be bioequivalent to the reference product with respect to all pharmacokinetic variables investigated.

Key words

Antihypertensive agents - CAS 54187-04-1 - CAS 85409-38-7 - Hyperium® - Rilmenidine, bioavailability, bioequivalence, pharmacokinetics - Rilmenidine dihydrogen phosphate

• Literature

• 1 Sweetman SC (ed.) Martindale: The Extra Pharmacopoeia. pp 996 34th edition London: The Pharmaceutical Press; 2005
• 2 Servier. Summary of product characteristics: Hyperium®. Available at http://www.servier.com Assessed on 21 May 2007.
• 3 Aparico M, Dratwa M, El Esper N, Fillastre JP, Levaltier B, Lins R et al. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol. 1994; 74: 43A-50A
• 4 Reid JL, Panfilov V, MacPhee G, Elliot HL. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors: Studies with clonidine, moxonodine, rilmenidine and atenolol. Annals of the New York Academy of Science. 1995; 763: 673-678
• 5 Reid JL. Update on rilmenidine: Clinical benefits. Am J Hypertens. 2001; 14 (11:Suppl 1) S322-S324
• 6 Genissel P, Bromet N, Fourtillan JB, Mignot A, Albin H. Pharmacokinetics of rilmenidine in healthy subjects. Am J Cardiol. 1988; 61 (7) 47D-53D
• 7 Singlas E, Ehrhardt JD, Zech P, Pozet N, Genissel P. Pharmacokinetics of rilmenidine. Am J Cardiol. 1988; 61 (7) 54D-59D
• 8 Louis WJ. Sympathetic nervous system as a pharmacological target for centrally acting antihypertensive drugs. Sympathetic system review.
• 9 Genissel P, Bromet N. Pharmacokinetics of rilmenidine. Am J Med. 1989; 87 (Suppl. 3C) 18S-23S
• 10 Rilmenidine – Wikipedia. Available at http://en.wikipedia.org/wiki/rilmenidine Assessed on 21 May 2007.
• 11 Safar ME. Rilmenidine: A novel antihypertensive agent. Am J Med. 1989; 87 (Suppl. 3C) 24S-29S
• 12 ICH Guideline for Good Clinical Practice, ICH Harmonised Tripartite Guideline (CPMP/ICH/135/95) (1997).
• 13 Note for Guidance on investigation of bioavailability and bioequivalence, ICH Secretariat (CPMP/EWP/QWP/1401/978) (2001).
• 14 Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J of Clin Pharm. 1983; 24: 27-136
• 15 Department of Health, South Africa. Guidelines for Good Practice in the conduct of clinical trials in human participants in South Africa (2000).
• 16 Standards for the practice of blood transfusion in South Africa, Chapter B. Blood Donors, 3rd edition. 1999. p. 9.
• 17 Steinijans VW, Hauscke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 105-110
• 18 SAS Institute INC, SAS/STAT Guide for Personal Computers, version 6.12, 4th Ed, Cary, NC: SAS Institute Inc (1990).
• 19 Hauscke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-78